Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kaye

Showing results (331-340 of 411) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Oral Surgery, Oral Medicine, and Oral Pathology|November 1, 1984
The effect of cytotoxic therapy on saliva and oral floraB E Main, K C Calman, M M Ferguson, et al.
Hematological Oncology|January 1, 1990
The myelotoxicity of carboplatin is influenced by the time of its administrationD J Kerr, C Lewis, B O'Neil, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analoguesD Cunningham, C J Bradley, G J Forrest, et al.
British Journal of Cancer|April 1, 1992
Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials CommitteeS B Kaye, M Brampton, P Harper, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1984
Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized studyJ A Elliott, S Ahmedzai, D Hole, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
Lancet (London, England)|September 3, 1988
Carboplatin or cisplatin?A H Calvert, A Horwich, E S Newlands, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lungD Cunningham, S W Banham, A H Hutcheon, et al.
Pageof 42

Showing results (331-340 of 411) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials GroupU Bruntsch, B Heinrich, S B Kaye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 1997
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeksS Senan, R Rampling, M A Graham, et al.
Oral Surgery, Oral Medicine, and Oral Pathology|November 1, 1984
The effect of cytotoxic therapy on saliva and oral floraB E Main, K C Calman, M M Ferguson, et al.
Hematological Oncology|January 1, 1990
The myelotoxicity of carboplatin is influenced by the time of its administrationD J Kerr, C Lewis, B O'Neil, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analoguesD Cunningham, C J Bradley, G J Forrest, et al.
British Journal of Cancer|April 1, 1992
Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials CommitteeS B Kaye, M Brampton, P Harper, et al.
European Journal of Cancer & Clinical Oncology|August 1, 1984
Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized studyJ A Elliott, S Ahmedzai, D Hole, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trialM A Graham, S Senan, H Robin, et al.
Lancet (London, England)|September 3, 1988
Carboplatin or cisplatin?A H Calvert, A Horwich, E S Newlands, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lungD Cunningham, S W Banham, A H Hutcheon, et al.
Pageof 42